摘要
目的 讨论Luminal型乳腺癌中PD-L1、CD8^(+)T淋巴细胞的表达特点及预测价值。方法 收集2022年1月至2023年10月于本院治疗的Luminal型乳腺癌病例共54例。收集患者临床资料(年龄、家族史、合并症等),病理资料(TNM分期、PR%、病理学分级等),使用Cox生存分析判断生存的独立因素。结果 Luminal型乳腺癌患者CD8^(+)T表达在绝经状态、肿瘤分期、Ki-67方面有统计学差异,肿瘤细胞中程序性死亡配体1(programmed death ligand 1,PD-L1)的表达与TNM分期、TIL评分、PR%、Ki-67、分子分型相关,肿瘤浸润淋巴细胞(tumor infiltrating lymphocytes,TILs)中PD-L1的表达TNM分期、TIL评分、PR%、Ki-67、分子分型、ER%相关,CD8^(+)T表达与肿瘤细胞、TILs中PD-L1的表达有统计学差异,Luminal型乳腺癌患者生存的独立危险因素包括PR%、IC评分、Ki-67和病理学分级。结论 CD8^(+)T淋巴细胞抑制Luminal型乳腺癌的增殖和转移,PD-L1在TILs中的表达、PR%、Ki-67和病理学分级对Luminal型乳腺癌患者的生存预后具有一定的预测价值。
Objective To discuss the expression characteristics and predictive value of PD-L1 and CD8^(+)T lymphocytes in Luminal type breast cancer.Methods A total of 54 cases of Luminal type breast cancer treated in our hospital from January 2022 to October 2023 were collected.Clinical data(age,family history,comorbidities,etc.),pathologic data(TNM stage,PR%,pathologic grading,etc.) were collected,and independent factors of survival were determined using Cox survival analysis.Results CD8^(+)T expression in Luminal type breast cancer patients was statistically different in terms of menopausal status,tumor stage,Ki-67,and programmed death ligand 1(PD-L1) in tumor cells expression in tumor cells correlated with TNM stage,TIL score,PR%,Ki-67,molecular typing,PD-L1 expression in tumor infiltrating lymphocytes(TILs) TNM stage,TIL score,PR%,Ki-67,molecular typing,ER%,and CD8^(+)T expression correlated with tumor cells,PD-L1 expression in TILs was statistically different,and independent risk factors for survival in patients with Luminal type breast cancer included PR%,IC score,Ki-67,and pathologic grading.Conclusion CD8^(+)T lymphocytes inhibited proliferation and metastasis of Luminal-type breast cancer,and PD-L1 expression in TILs,PR%,Ki-67,and pathologic grade had predictive value for survival prognosis of Luminal-type breast cancer patients.
作者
杨筱绯
王路军
吴桔红
YANG Xiaofei;WANG Lujun;WU Juhong(People's Hospital Of Anji,Zhejiang 313300,China)
出处
《浙江创伤外科》
2024年第4期610-613,共4页
Zhejiang Journal of Traumatic Surgery
基金
浙江省湖州市科技局计划项目(2022GY57)。
